ICAAC 2010
Maraviroc Failure with Co-receptor Switch Does Not Lead to HIV Disease Progression
- Details
- Category: HIV Treatment
- Published on Tuesday, 21 September 2010 13:46
- Written by Liz Highleyman
People with HIV strains that switch from CCR5 to CXCR4 co-receptor use during treatment with the CCR5 antagonist maraviroc (Selzentry) do not experience adverse outcomes including subsequent treatment failure or HIV disease progression, according to findings from the MERIT study presented last week at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010) in Boston.
End-of-Treatment Response to Interferon-based Therapy Reduces Liver Failure and Death in HIV/HCV Coinfected Patients
- Details
- Category: HIV/HCV Coinfection
- Published on Tuesday, 21 September 2010 12:46
- Written by Liz Highleyman
HIV/HCV coinfected individuals who experience an end-of-treatment response to interferon-based therapy for chronic hepatitis C virus (HCV) infection had a greatly reduced risk of liver decompensation and liver-related death, even if they did not go on to achieve sustained virological response, according to a Spanish study presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010) last week in Boston.
Use of CCR5 Antagonist Does Not Explain Better CD4 Cell Recovery with Newer Antiretroviral Drugs
- Details
- Category: HIV Treatment
- Published on Friday, 17 September 2010 17:00
- Written by Liz Highleyman
HIV positive people using today's state-of-the-art antiretroviral drugs are likely to achieve good CD4 cell recovery, but this cannot be attributed specifically to use of CCR5 antagonists such as maraviroc (Selzentry), according to a presentation at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010) this week in Boston.
Worse Fibrosis Predicts Death in HIV/HCV Coinfected Individuals, Interferon Therapy Lowers Risk
- Details
- Category: HIV/HCV Coinfection
- Published on Tuesday, 21 September 2010 09:17
- Written by Liz Highleyman
HIV/HCV coinfected individuals with more advanced fibrosis have shorter survival than those with less liver damage, but treatment with interferon-based therapy reduces mortality risk, according to findings from a Spanish study presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010) recently held in Boston.
HIV Infection Linked to Increased Cardiovascular Risk Even in Long-term Non-progressors
- Details
- Category: Cardiovascular Disease
- Published on Friday, 17 September 2010 13:46
- Written by Liz Highleyman
Markers of endothelial dysfunction -- an early indicator of cardiovascular disease -- were elevated in HIV positive people who maintained a stable viral load and CD4 cell count without antiretroviral therapy (ART), and even among "elite controllers," according to a study presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010) this week in Boston. This finding adds further evidence that factors other than waning CD4 T-cell function -- for example, persistent inflammation -- contribute to non-AIDS conditions in the ART era.
Web Design and Development by